Haga Susanne B, Beskow Laura M
Institute for Genome Sciences and Policy, Center for Genome Ethics, Law, and Policy, Duke University, Durham, NC 27708, USA.
Adv Genet. 2008;60:505-44. doi: 10.1016/S0065-2660(07)00418-X.
The elucidation of the causes of complex diseases pivots on understanding the interaction between biological (genetic) and environmental factors that give rise to disease risk. The modest effects of genetic factors in complex diseases supports the need for large-scale studies of high-quality human biological materials, paired with detailed clinical data, to adequately detect these effects. To this end, biobanks or biorepositories have been developed around the world, by public and private entities alike, to provide researchers the opportunity to study collections of human biospecimens annotated with clinical and other health-related measurements. It has been estimated that more than 270 million tissue samples are stored in the U.S., expanding at a rate of approximately 20 million samples annually. In this chapter, we discuss several ethical, legal, and social issues that have been raised surrounding biobanks, including recruitment of vulnerable populations, informed consent, data disclosure to participants, intellectual property, and privacy and security. Throughout the chapter, we will highlight experiences of national biobanks in Iceland, the U.K., Sweden, and Estonia, and the proposal for a U.S. population cohort study. The dependence on public participation requires clear and transparent policies developed through inclusive processes.
复杂疾病病因的阐明关键在于理解导致疾病风险的生物(遗传)因素与环境因素之间的相互作用。遗传因素在复杂疾病中作用较小,这就需要对高质量的人类生物样本进行大规模研究,并结合详细的临床数据,以充分检测这些影响。为此,世界各地的公共和私人机构都建立了生物样本库或生物资源库,为研究人员提供机会,以便他们研究那些标注有临床及其他健康相关测量数据的人类生物样本集合。据估计,美国存储了超过2.7亿份组织样本,且每年以约2000万份样本的速度增长。在本章中,我们将讨论围绕生物样本库引发的若干伦理、法律和社会问题,包括弱势群体的招募、知情同意、向参与者的数据披露、知识产权以及隐私与安全等问题。在整章内容中,我们将重点介绍冰岛、英国、瑞典和爱沙尼亚国家生物样本库的经验,以及美国一项人群队列研究的提议。对公众参与的依赖需要通过包容性程序制定清晰透明的政策。